ES2192128A1 - Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia. - Google Patents

Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.

Info

Publication number
ES2192128A1
ES2192128A1 ES200100997A ES200100997A ES2192128A1 ES 2192128 A1 ES2192128 A1 ES 2192128A1 ES 200100997 A ES200100997 A ES 200100997A ES 200100997 A ES200100997 A ES 200100997A ES 2192128 A1 ES2192128 A1 ES 2192128A1
Authority
ES
Spain
Prior art keywords
human
monoclonal antibody
molecule
therapy
specifically recognizes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200100997A
Other languages
English (en)
Other versions
ES2192128B1 (es
Inventor
Fernandez Africa Gonzalez
Andrade Monica Valladares
Ocana Ana Molina
Deza Francisco Gambon
Mompo Susana Magadan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Vigo
Original Assignee
Universidade de Vigo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Vigo filed Critical Universidade de Vigo
Priority to ES200100997A priority Critical patent/ES2192128B1/es
Publication of ES2192128A1 publication Critical patent/ES2192128A1/es
Application granted granted Critical
Publication of ES2192128B1 publication Critical patent/ES2192128B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Anticuerpo monoclonal humano haIM-29 que reconoce la molécula humana CD69, y su uso en terapia humana. Un nuevo hibridoma, designado H69, productor de un anticuerpo monoclonal humano hAIM- 29 (de isotipo IgM / lambda). El anticuerpo reconoce de forma específica a la molécula humana CD69, que es un antígeno de activación muy temprano linfocitario. El hibridoma H69 se generó por fusión de células del mieloma murino NSO con células de bazo de un ratón transgénico portador de secuencias de inmunoglobulinas humanas que había sido inmunizado con una suspensión de células de rata transfectadas con la molécula humana CD69. El clon fue seleccionado por su patrón de reconocimiento celular por inmunofluorescencia indirecta frente a las células de rata transfectadas y frente a linfocitos activados humanos. La presente invención podría utilizarse para tratamiento de patologías humanas que conlleve gran activación linfocitaria (enfermedades autoinmunes como la artritis reumatoide u otras patologías de tipo inflamatorio).
ES200100997A 2001-04-27 2001-04-27 Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia. Expired - Fee Related ES2192128B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200100997A ES2192128B1 (es) 2001-04-27 2001-04-27 Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100997A ES2192128B1 (es) 2001-04-27 2001-04-27 Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.

Publications (2)

Publication Number Publication Date
ES2192128A1 true ES2192128A1 (es) 2003-09-16
ES2192128B1 ES2192128B1 (es) 2005-01-01

Family

ID=28051947

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100997A Expired - Fee Related ES2192128B1 (es) 2001-04-27 2001-04-27 Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.

Country Status (1)

Country Link
ES (1) ES2192128B1 (es)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244297A1 (es) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Mejoras introducidas en la patente de invencion n. 200300252 correspondiente a una nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
WO2008077355A1 (es) * 2006-12-26 2008-07-03 Centro De Inmunolgía Molecular Composición farmaceutica que comprende un anticuerpo monoclonal anti-cd6 utilizado en el diagnóstico y tratamiento de la artritis reumatoide
US7867475B2 (en) 2003-01-31 2011-01-11 Universidad Autonoma De Madrid Immune regulation based on the depletion of CD69+ cells
US10000573B2 (en) 2008-03-14 2018-06-19 Centro De Immunologia Molecular Monoclonal antibody and a method thereof
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033735A1 (en) * 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1999045962A1 (en) * 1998-03-13 1999-09-16 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033735A1 (en) * 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1999045962A1 (en) * 1998-03-13 1999-09-16 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANCHO D. et al. Functional Analysis of Ligand-Binding and Signal Transduction Domains of CD69 and CD23 C-Type Lectin Leukocyte Receptors. J. Immunol., Octubre 2000, Vol. 165, Nö 7, páginas 3868-3875. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244297A1 (es) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Mejoras introducidas en la patente de invencion n. 200300252 correspondiente a una nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
ES2244270A1 (es) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
US7867475B2 (en) 2003-01-31 2011-01-11 Universidad Autonoma De Madrid Immune regulation based on the depletion of CD69+ cells
US8182816B2 (en) 2003-01-31 2012-05-22 Universidad Autonoma De Madrid Methods of treating cancer
WO2008077355A1 (es) * 2006-12-26 2008-07-03 Centro De Inmunolgía Molecular Composición farmaceutica que comprende un anticuerpo monoclonal anti-cd6 utilizado en el diagnóstico y tratamiento de la artritis reumatoide
US10000573B2 (en) 2008-03-14 2018-06-19 Centro De Immunologia Molecular Monoclonal antibody and a method thereof
US10669346B2 (en) 2008-03-14 2020-06-02 Biocon Limited Monoclonal antibody and a method thereof
US11981743B2 (en) 2008-03-14 2024-05-14 Biocon Limited Monoclonal antibody and a method thereof
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
US11028168B2 (en) 2013-07-23 2021-06-08 Biocon Limited Use of a CD6 binding partner and method based thereon
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus

Also Published As

Publication number Publication date
ES2192128B1 (es) 2005-01-01

Similar Documents

Publication Publication Date Title
Mix et al. Immunoglobulins—basic considerations
PT1425389E (pt) Anticorpos humanos específicos para interleucina 15 (il-15)
Chu et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody
RU2504552C2 (ru) Моноклональные антитела против il-21 человека
RU2010130994A (ru) Агенты против клетки-мишени, нацеленные на cd138, и их применение
HRP20181069T1 (hr) Antagonistička protutijela na il-17
AR052065A1 (es) Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos
NZ568403A (en) CD20-specific antibodies and methods of employing same
AR079458A2 (es) Anticuerpo monoclonal quimerico que se une a cd45
ATE160379T1 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
WO2007103470A3 (en) Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
RU2007139953A (ru) Антитела к ccr5 и их применение
DE60137210D1 (de) Verfahren von antikörper mit adcc via cd16, z.b. monoklonale antikörper gegen rhesus d
LT2005099A (en) Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof
PE20030104A1 (es) Anticuerpos humanos para cd154
PE20120835A1 (es) Anticuerpos anti-tnf-alfa y sus usos
RU2005132389A (ru) Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
RU2016151645A (ru) Биспецифические гетеродимерные диантитела и их применение
DK0812333T3 (da) Bispecifikt antistof, som er effektivt til behandling af B-cellelymfom og cellelinie
EA200500835A1 (ru) Человеческие моноклональные антитела против cd25
RU2018137110A (ru) Антитела против psma и их применение
RU2012128856A (ru) Мыши, которые производят антитела, имеющие только тяжелую цепь
CO6251371A2 (es) Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino
NO20066052L (no) Anti-CD3 antistoffer og fremgangsmater for anvendelse derav

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030916

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192128B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20210803